Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
PureTech Health welcomed news that affiliate company Akili had published positive trial results for a treatment for attention-deficit/hyperactivity disorder in The Lancet Digital Health journal.
The publication represented the first presentation of complete results from the trial.
Results showed the treatment, AKL-T01, improved both objective measures and parent observations of attention and functional impairments.
At 9:33am: (LON:PRTC) Puretech Health PLC share price was -6.5p at 329.5p